Covid Clinical Trials 2023
Here are the 6 most popular medical studies for covid19
Virus Therapy
Recombinant Protein COVID-19 Vaccines for COVID-19
This trial is testing two types of vaccines to see if they are effective in adults, as well as if they are safe and have few side effects. The trial will last for 365 days after the last initial injection, and participants may be asked to continue for an additional 12 months if they received the vaccine.
Vitamin Supplement
Vitamin D for COVID-19
This trial is testing whether vitamin D supplements can reduce the rate of people seeking healthcare for symptoms related to COVID-19, and whether it can reduce the risk of infection with the virus in people who have been recently diagnosed with COVID-19.
Popular filter options for covid19 trials
COVID-19 Clinical Trials
View 100 COVID-19 medical studies.
Monoclonal Antibodies
EB05 for Hospitalized COVID-19 Patients
This trial is testing a potential new treatment, EB05, for people who have been hospitalized with COVID-19. The treatment is designed to target the initial step in the signalling pathways of these DAMPs in innate immunity.
Tyrosine Kinase Inhibitor
Imatinib for COVID-19
This trial is testing if a drug called imatinib is safe and effective for treating people hospitalized with COVID-19. The trial is randomized, which means that people are assigned by chance to either receive imatinib or a placebo (a medicine with no active ingredient). Neither the participants nor the researchers will know who is receiving imatinib or the placebo until the trial is over.
Coronavirus Clinical Trials
View 95 Coronavirus medical studies.
Monoclonal Antibodies
EB05 for Hospitalized COVID-19 Patients
This trial is testing a potential new treatment, EB05, for people who have been hospitalized with COVID-19. The treatment is designed to target the initial step in the signalling pathways of these DAMPs in innate immunity.
Tyrosine Kinase Inhibitor
Imatinib for COVID-19
This trial is testing if a drug called imatinib is safe and effective for treating people hospitalized with COVID-19. The trial is randomized, which means that people are assigned by chance to either receive imatinib or a placebo (a medicine with no active ingredient). Neither the participants nor the researchers will know who is receiving imatinib or the placebo until the trial is over.
Phase 3 Covid19 Clinical Trials
View 100 phase 3 covid19 medical studies.
Monoclonal Antibodies
EB05 for Hospitalized COVID-19 Patients
This trial is testing a potential new treatment, EB05, for people who have been hospitalized with COVID-19. The treatment is designed to target the initial step in the signalling pathways of these DAMPs in innate immunity.
Tyrosine Kinase Inhibitor
Imatinib for COVID-19
This trial is testing if a drug called imatinib is safe and effective for treating people hospitalized with COVID-19. The trial is randomized, which means that people are assigned by chance to either receive imatinib or a placebo (a medicine with no active ingredient). Neither the participants nor the researchers will know who is receiving imatinib or the placebo until the trial is over.
Virus Therapy
DAS181 for Respiratory Infections
This trial will enroll immunocompromised patients with Lower Tract parainfluenza infection to study the safety and efficacy of an investigational vaccine. A sub-study will also enroll patients with severe COVID-19.
View More Covid19 Trials
See another 77 medical studies focused on covid19.
Frequently Asked Questions
Introduction to covid19
What are the top hospitals conducting covid19 research?
In the battle against the global COVID-19 pandemic, hospitals and research centers have been at the forefront of scientific innovation. One such institution leading the charge is the University of Minnesota in Minneapolis. With five active clinical trials focused on COVID-19, this renowned hospital is dedicated to finding effective treatments and solutions for this unprecedented health crisis. Similarly, Sunnybrook Health Sciences Centre in Toronto is making significant contributions with three ongoing trials aimed at combating COVID-19. Located in Tampa, Florida, Tampa General Hospital joins the effort with three active clinical trials as well. Meanwhile, UF Health Precision Health Research located in The Villages community also has three current studies underway to aid our understanding and ability to combat this virus effectively. Lastly, Morehouse School of Medicine based in Atlanta proudly contributes its expertise through three active clinical trials targeting COVID-19.
Although these hospitals may not have any completed or all-time recorded trials specific to COVID-19 yet due to its recent emergence as a global threat; their commitment exemplifies an unwavering determination toward developing strategies that can save lives during this challenging time. By conducting rigorous research and enrolling patients into these innovative studies, these institutions are paving the way for groundbreaking breakthroughs that will shape our future response to pandemics like never before seen
Which are the best cities for covid19 clinical trials?
When it comes to COVID-19 clinical trials, several cities have emerged as hubs of research and development. Chicago, with 14 active trials, is investigating treatments such as Nitazoxanide and SARS-CoV-2 rS/Matrix-M1 Adjuvant. Miami follows closely behind with 13 ongoing studies focused on interventions like Fluvoxamine and SARS-CoV-2 rS/Matrix-M1 Adjuvant. Toronto also plays a significant role in COVID-19 research, with 11 active trials exploring methods such as PRONE POSITIONING and Sevoflurane inhalant product. New york City and Philadelphia are also notable cities for COVID-19 clinical trials, conducting investigations into various treatment options. These cities collectively provide individuals affected by the pandemic access to cutting-edge clinical trials that contribute to advancing our understanding of the virus and potential treatments for better outcomes.
Which are the top treatments for covid19 being explored in clinical trials?
Researchers are leaving no stone unturned in the quest for effective treatments against COVID-19. At the forefront of clinical trials, several potential game-changers have emerged. Here are a few leading contenders:
- Remdesivir: A widely studied antiviral drug showing promise in mitigating severe symptoms.
- Tocilizumab: An immunosuppressive medication that aims to counteract harmful inflammation caused by the virus.
- Convalescent plasma therapy: The transfusion of antibody-rich plasma from recovered COVID-19 patients with hopes of boosting immunity.
As scientists continue their relentless efforts, these treatments offer glimpses of hope amidst the ongoing battle against this global pandemic.
What are the most recent clinical trials for covid19?
Recent clinical trials for COVID-19 have brought forth promising advancements in the fight against this global pandemic. Notably, significant attention has been given to the potential benefits of metformin, an existing medication used for diabetes management, in mitigating the impact of COVID-19. Another trial focused on intravenously delivering MSC-exosomes every other day at escalating doses, displaying encouraging results during phases 1 and 2. Additionally, Azelastine has been investigated as a treatment option for COVID-19 in a Phase 4 trial. These developments indicate that progress is being made towards finding effective interventions to combat this unprecedented health crisis.
What covid19 clinical trials were recently completed?
Several recent clinical trials have made significant progress in advancing our understanding and treatment of COVID-19. Notably, a trial for the antiviral drug Remdesivir concluded successfully, providing valuable insights into its effectiveness against the virus. Another important trial investigated the use of convalescent plasma therapy, which utilizes antibodies from recovered COVID-19 patients to treat those currently infected. Additionally, a study explored the potential benefits of dexamethasone as an anti-inflammatory treatment for severe cases of COVID-19. These completed trials contribute to our ongoing fight against the pandemic by informing medical strategies and improving patient outcomes.